CN Patent

CN108498532B — 骨髓抑制的治疗

Assigned to Cantex Pharmaceuticals Inc · Expires 2021-07-23 · 5y expired

What this patent protects

本发明提供了通过给药与PF4相互作用的类肝素来减弱治疗方案的骨髓抑制副作用、促进血小板生成和中性粒细胞的产生以及增加治疗方案疗效的方法。

USPTO Abstract

本发明提供了通过给药与PF4相互作用的类肝素来减弱治疗方案的骨髓抑制副作用、促进血小板生成和中性粒细胞的产生以及增加治疗方案疗效的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN108498532B
Jurisdiction
CN
Classification
—
Expires
2021-07-23
Drug substance claim
No
Drug product claim
No
Assignee
Cantex Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.